Loading
LT
LAVA Therapeutics NV Stock: price and insider trades · United States
LAVA Therapeutics NV: what insiders have been doing
LAVA Therapeutics NV belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 22 October 2026, brought 4 filings signed by 4 insiders.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Insider buying of LAVA Therapeutics NV has been absent for the past year. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction.
For context, the typical company on the same exchange (median of 3,171 companies) published 24 filings over the same period, against 4 filings here. The full history, which starts in 2025, counts no purchases against 17 sales.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
21
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€10M
17 ops. · all time
Who traded when
BuySaleVersant Venture Capital VI, L.P.8 sales
Gilde Healthcare IV U.A. Cooperatieve7 sales
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
RevenueUS$10.3M
Gross profitUS$2.8M27% margin
Net income-US$21.6M-209.6% margin
Last declaration on 17 November 2025
Declarations21 total
30,000 sharesCommon SharesSEC:0001456849-25-000005:0
10,000 sharesCommon SharesSEC:0001267490-25-000006:0
5,000 sharesCommon SharesSEC:0001130637-25-000005:0
65,000 sharesCommon SharesSEC:0001331339-25-000005:0
1,000,000 shares@ US$1.46Common SharesSEC:0001193125-25-243899:2
1,181,131 shares@ US$1.4751.3% of flowCommon SharesSEC:0001193125-25-243899:1
690,239 shares@ US$1.4989.6% of flowCommon SharesSEC:0001193125-25-243899:0
227,341 shares@ US$1.5110.2% of flowCommon SharesSEC:0001193125-25-240610:1
200,000 shares@ US$1.51Common SharesSEC:0001193125-25-240610:2
47,686 shares@ US$1.546.5% of flowCommon SharesSEC:0001193125-25-240610:0
48,169 shares@ US$1.562.2% of flowCommon SharesSEC:0001193125-25-237275:1
49,869 shares@ US$1.552.3% of flowCommon SharesSEC:0001193125-25-237275:2
28,954 shares@ US$1.574.0% of flowCommon SharesSEC:0001193125-25-237275:0
532,870 shares@ US$1.401411.4% of flowCommon StockSEC:0001193125-25-213445:1
2,370,533 shares@ US$1.401487.6% of flowCommon StockSEC:0001193125-25-213445:0
192,293 shares@ US$1.53324.5% of flowCommon StockSEC:0001193125-25-207677:1
362,806 shares@ US$1.48928.2% of flowCommon StockSEC:0001193125-25-207677:2
226,726 shares@ US$1.48925.1% of flowCommon StockSEC:0001193125-25-207677:3
366,111 shares@ US$1.44188.0% of flowCommon StockSEC:0001193125-25-207677:4
228,791 shares@ US$1.44185.0% of flowCommon StockSEC:0001193125-25-207677:5
307,707 shares@ US$1.533212.4% of flowCommon StockSEC:0001193125-25-207677:0
21 of 21 declarations
About LAVA Therapeutics NV
LAVA Therapeutics N.V. (NASDAQ: LVTX) is a clinical-stage biotechnology company focused on immuno-oncology, with headquarters in Utrecht, the Netherlands, and operational presence in Philadelphia, Pennsylvania, United States. For French, Belgian, and Swiss investors, the stock fits the profile of a small-cap NASDAQ-listed biotech whose valuation is primarily driven by clinical milestones, partnership economics, and strategic transactions rather than recurring commercial sales. Founded in 2016, LAVA was built around its proprietary Gammabody® platform, designed to create bispecific gamma delta T-cell engagers that activate Vγ9Vδ2 gamma-delta T cells and redirect that immune response toward cancer cells.
The company’s business model centers on the development of novel immuno-oncology therapies for both solid tumors and hematologic malignancies. Its scientific concept aims to combine target specificity with potentially improved tolerability relative to some conventional T-cell engager approaches. LAVA has historically advanced a small set of internal and partnered programs, including LAVA-051, LAVA-1207, and LAVA-1266, alongside assets licensed or co-developed with major pharmaceutical partners such as Pfizer and Johnson & Johnson. That mix of proprietary and partnered programs matters strategically: it can diversify scientific risk while also providing potential milestone revenue and collaboration income.
Read moreShow less
From a competitive standpoint, LAVA operates in a highly crowded field that includes large pharmaceutical companies, platform biotechs, and specialist oncology innovators pursuing bispecific antibody technologies. Its differentiation lies in a relatively unusual biology: LAVA positions itself as the only company developing bispecific gamma delta T-cell engaging antibodies for cancer. That gives it a distinct scientific identity, but also exposes investors to the high risk that comes with a concentrated, clinically driven pipeline.
Recent developments are especially relevant. In 2025, LAVA announced that it was evaluating strategic alternatives, and later entered into an acquisition agreement with XOMA Royalty Corporation, under which shareholders may receive cash consideration plus a contingent value right tied to selected assets. The company also disclosed the discontinuation of LAVA-1266 in acute myeloid leukemia and myelodysplastic syndromes, reflecting a tighter focus on capital allocation and portfolio prioritization. Recent updates have emphasized cash preservation, partnership value creation, and the optionality embedded in its partnered assets. In practical terms, LAVA should be viewed as a NASDAQ-listed U.S.-market biotech exposure with significant event-driven upside and downside, dependent on clinical execution, deal completion, and the monetization of its platform assets.
